Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus by Seewoodhary, Jason et al.
© 2010 Seewoodhary et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access  
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 165–172
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
165
Review
open access to scientific and medical research
Open Access Full Text Article
7493
Critical appraisal of once-weekly formulation 
of exenatide in the control of type 2 diabetes 
mellitus
Jason Seewoodhary1 
Leanne Griffin1 
Stephen C Bain1
1Department of Diabetes and 
endocrinology, Swansea School 
of Medicine, University of wales, 
Swansea SA2 8PP, UK
Correspondence: Jason Seewoodhary 
Department of Diabetes and 
endocrinology, Swansea School of 
Medicine, University of wales, The Grove 
Building, Swansea SA2 8PP, UK 
Tel +44 01792 205666 
email seewoodharyj@hotmail.com
Abstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which 
is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation 
of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered 
within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being 
assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin 
monotherapy to achieve glycosylated hemoglobin levels of ,7% in .75% of treated patients. 
It has also demonstrated potential cardiovascular benefits by lowering total and low-density 
lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood 
pressure. In addition, patients treated with exenatide QW achieved significant weight loss, 
which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated 
with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and 
no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic 
event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known 
to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. 
This review defines the state of play with exenatide QW by critically appraising its role in 
clinical practice.
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Introduction
Type 2 diabetes mellitus is currently recognized as one of the main threats to human 
health worldwide, with the prevalence increasing in an epidemic fashion.1,2
General management issues in type 2 diabetes mellitus include education, diet, 
exercise, and weight loss. The latest treatment recommendations3 suggest a target 
glycosylated hemoglobin (HbA1c) level #7%, which has been shown to reduce 
microvascular complications of type 1 diabetes mellitus. Long-term follow-up of 
cohorts in the Diabetes Control and Complications Trial4 and UK Prospective Diabetes 
Study5 suggests that the treatment to HbA1c targets at this level in the years soon after 
the diagnosis of diabetes mellitus is associated with long-term reduction in the risk 
of macrovascular disease. Until more evidence becomes available, the general target 
level of ,7% appears reasonable for most adults with type 2 diabetes mellitus.
Despite the availability of many antidiabetic agents, approximately 60% of 
  individuals with diabetes mellitus do not achieve the target HbA1c levels.6 The reasons 
for this include noncompliance, side effects of treatments, hypoglycemia, weight gain, 
problems with dose titration of antidiabetic agents, and changing and more stringent 
target HbA1c levels by national healthcare organizations. Clearly, additional   therapeutic Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
166
Seewoodhary et al
options are needed, preferably the ones that will further 
improve glycemic control, reduce weight, and overcome 
other clinical shortcomings of available agents, especially 
hypoglycemia.
Incretin therapeutics are a relatively novel field and much 
remains to be discovered. This review examines the potential 
role of once-weekly exenatide (exenatide QW) formulation 
in the control of type 2 diabetes mellitus.
The incretin system, glucagon-like 
peptide-1, and exenatide
Incretins are a group of hormones released into the   bloodstream 
from gastrointestinal L and K cells in response to a nutrient 
load.7 They cause a postprandial increase in the amount of 
insulin released from the β-cells of the islets of Langerhans 
even before blood glucose levels become elevated but act 
in a glucose-dependent manner, thereby limiting the risk 
of hypoglycemia.7 Incretins have other benefits on glucose 
metabolism.7 They slow the rate of absorption of nutrients into 
the bloodstream by reducing gastric emptying; reduce satiety, 
which aids weight loss; and inhibit glucagon release from 
the α-cells of the islets of Langerhans.7 The two molecules 
that are recognized to have incretin effects are glucagon-
like peptide-1 (GLP-1) and gastric inhibitory peptide (also 
known as glucose-dependent insulinotropic peptide [GIP]).7 
Postprandial   augmentation of insulin secretion by GLP-1 and 
GIP – the so-called incretin effect – is reduced in patients 
with type 2 diabetes mellitus.8 However, in patients with 
newly diagnosed type 2 diabetes mellitus with relatively good 
  glycemic control (HbA1c   levels of approximately 6.9%), both 
GIP secretion and GLP-1 secretion in response to glucose 
and   mixed-meal challenges are the same or increased when 
compared with healthy subjects.9 Furthermore, in patients with 
long-standing type 2 diabetes mellitus with relatively poor 
glycemic control (HbA1c levels of approximately 8%–9%), 
the GLP-1   secretion is decreased, whereas the GIP secretion 
is unchanged.10 However, exogenous GLP-1 administration at 
pharmacological doses increases insulin secretion to normal 
levels and decreases plasma glucose effectively.11 In contrast, 
exogenous GIP administration, even at supraphysiological 
doses, has markedly reduced insulinotropic actions, with 
little or no glucose-lowering effects in patients with type 2 
diabetes mellitus.11 Therefore, therapeutic strategies for type 2 
diabetes mellitus are focused on the use of GLP-1 analogs, 
GLP-1 receptor (GLP-1R) agonists or GLP-1 mimetics, and 
not on the use of GIP.
The major drawback of using GLP-1 in the treatment of 
type 2 diabetes mellitus is its short half-life of   approximately 
2 minutes.12 GLP-1 is rapidly degraded by   dipetidyl 
  peptidase-4 (DPP-4), which cleaves the N-terminal   dipeptides 
(His7–Ala8) from GLP-1 (7–36) and renders the result-
ing major metabolite GLP-1 (9–36) inactive.13 In   addition, 
  neutral endopeptidase 24.11 hydrolyzes GLP-1 at six   different 
  moieties.14 Because of such a short half-life, bolus subcutane-
ous injections of GLP-1 result in only a transient effect on 
insulin secretion and plasma glucose levels.15
The potential of using GLP-1-based therapy for type 2 
diabetes mellitus has been realized by the development of 
GLP-1 mimetics; these mimetics are resistant to DPP-4 
activity and thus have a longer half-life relative to endog-
enous GLP-1.
Exenatide, an incretin mimetic, is licensed as an adjunc-
tive therapy in patients with type 2 diabetes mellitus who take 
metformin and/or a sulphonylurea but who do not achieve 
adequate glycemic control.15 It offers a wide range of ben-
eficial glucoregulatory effects, including enhancement of 
glucose-dependent insulin secretion, restoration of first-phase 
insulin response, and suppression of inappropriately elevated 
glucagon secretion, thereby achieving HbA1c level reductions 
of 0.6%–0.8%.15 These effects were more pronounced earlier 
on in patients with diabetes mellitus and were attenuated if 
exenatide therapy was started at a later stage when the β-cell 
mass relatively depleted.15 By slowing gastric emptying and 
promoting satiety, exenatide also facilitates weight loss, 
which is important in obese patients in whom insulin may 
promote weight gain and worsen insulin resistance.16
Exenatide shares 53% amino acid homology to human 
GLP-1 and binds directly to GLP-1R.17 It binds more avidly 
to GLP-1R than to GLP-1 in GLP-1R-expressing cells.17 
  Placebo-controlled18 and comparator-controlled19 clinical 
  studies have demonstrated that exenatide improves   glycemic 
control and reduces body weight in patients with type 2   diabetes 
mellitus. These studies also showed improvement of surrogate 
measures of β-cell function.19 In addition, animal studies sug-
gested that exogenous GLP-1 has the ability to increase islet 
size, enhance β-cell proliferation, inhibit β-cell apoptosis, and 
regulate islet growth.15 These effects are   important because 
they increase the possibility that GLP-1 therapies may modify 
the progression of type 2 diabetes mellitus.
Short-acting exenatide (twice-daily exenatide [exenatide 
BID]) has been shown to be effective in lowering HbA1c 
level in a 30-week, randomized, AMIGO trials, which are 
summarized in Table 1.
Exenatide BID is administered by subcutaneous injection 
before each of the two main meals of the day, but may not 
provide complete coverage overnight and of midday meals.16 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Therefore, exenatide QW formulation has been developed. 
Exenatide QW incorporates a delivery technology that uses 
biodegradable polymeric microspheres to entrap exenatide 
and provide extended release of the medication.22 Once 
injected into the subcutaneous tissues, the microspheres 
  biodegrade over time, thereby releasing the bioactive 
  molecules in a controlled manner.22
The time to peak plasma and steady-state concentrations 
is increased with exenatide QW relative to exenatide BID.22 
Exenatide concentrations that significantly reduce fasting 
plasma glucose are achieved within 2 weeks of exenatide 
QW dosing, and plateau concentrations are achieved within 
6–10 weeks.22 The range of steady-state concentrations for 
exenatide QW encompasses the peak plasma concentrations 
observed for exenatide BID.22 As a result, exenatide QW 
results in 24-hour coverage with exenatide concentrations 
that are known to improve glycemic control and remain well 
tolerated in patients with type 2 diabetes mellitus.22
Efficacy of exenatide QW
Controlled clinical trials have demonstrated multiple effects 
of exenatide QW on glycemic control in patients with type 2 
diabetes mellitus. A small, dose-ranging clinical trial22 in 
patients unable to maintain adequate glycemic control with 
either diet and exercise alone or metformin monotherapy 
showed significant HbA1c level reductions and weight loss 
with exenatide QW. The trial consisted of a 15-week treatment 
phase, followed by a 12-week safety follow-up period, during 
which no drug was administered. Patients were randomized 
to placebo, 0.8 mg exenatide QW, and 2 mg exenatide QW. 
The study population had a mean HbA1c level of 8.5% and 
a mean disease duration of 5 years. At both does, exenatide 
QW resulted in an improved fasting plasma glucose and 
postprandial glycemic control and a significant reduction in 
HbA1c level, with final HbA1c levels of 7.2% and 6.6% for 0.8 
and 2 mg exenatide QW, respectively. Approximately 80% 
of the patients treated with 2 mg exenatide QW achieved an 
HbA1c level of ,7%, and there were significant reductions in 
body weight, with an average weight loss of 3.8 kg (compared 
with no weight loss in those who received 0.8 mg exenatide 
QW and placebo). However, this study was limited by the 
small sample size (n = 45).
In support of these findings, 2 mg exenatide QW 
  demonstrated significant reductions in HbA1c levels   compared 
with 10 µg exenatide BID at 30 weeks in the DURATION-1 
(Diabetes therapy Utilisation: Research changes in HbA1c, 
weight and other factors Through Intervention with exenatide 
Once weekly) study that included 295 patients with type 2 
diabetes mellitus.23 At 30 weeks, the patients given exenatide 
QW had significantly greater reductions in HbA1c levels than 
those given exenatide BID (P = 0.0023). A significantly 
greater proportion of patients receiving exenatide QW com-
pared with patients receiving exenatide BID achieved target 
HbA1c levels of ,7% (77% vs 61%, P = 0.0039), with no 
increased risk of hypoglycemia.
DURATION-1 study23 also reported important changes 
in cardiovascular disease (CVD) risk factors. Compared with 
the exenatide BID regimen, patients receiving exenatide 
QW had greater reductions from baseline in mean total and 
low-density lipoprotein cholesterol concentrations (−0.13% 
vs +0.03%). However, the clinical significance of these 
reductions is not clear because the confidence intervals are 
very broad. Both groups experienced similar reductions 
in triglycerides from baseline, similar reductions in blood 
pressure, and similar weight loss. However, the results of 
DURATION-1 study23 are limited by the lack of long-term 
data, especially on exenatide QW’s capacity to reduce 
  diabetic complications.
Data from DURATION-2 study24 have shown 2 mg 
exenatide QW to provide superior glycemic control and weight 
loss compared with sitagliptin (100 mg once daily [OD]) and 
pioglitazone (45 mg OD) in 491 patients   taking stable doses of 
Table 1 Summary of the AMiGO trials
Trial No. of  
participants
Exenatide + [drug]  
versus placebo + [drug]
Effect of 5 μg exenatide  
on HbA1c
Effect of 10 μg  
exenatide on HbA1c
Effect of placebo  
on HbA1c
AMiGO-120 336 Metformin 0.4% reduction 0.8% reduction 0.1% increase (P , 0.002 
vs placebo for both 
exenatide groups)
AMiGO-219 377 Sulphonylurea 0.5% reduction 0.9% reduction 0.1% increase (P , 0.001 
vs placebo for both  
exenatide groups)
AMiGO-321 733 Metformin and  
sulphonylurea
0.6% reduction 0.8% reduction 0.2% increase (P , 0.001 
vs placebo for both  
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metformin. Patients randomized to exenatide QW achieved a 
significantly lower HbA1c level from   baseline (1.7%) compared 
with those randomized to sitagliptin (1%) and pioglitazone 
(1.4%) at 26 weeks. The exenatide QW cohort also achieved 
statistically significant weight loss (−2.8 kg)   compared with 
the sitagliptin (−0.9 kg) and pioglitazone (+3.4 kg) cohorts at 6 
months. In addition, DURATION-2 study24 demonstrated that 
exenatide QW achieved target HbA1c levels, with no episodes 
of major hypoglycemia.
The unpublished DURATION-3 trial has compared the 
efficacy of 2 mg exenatide QW with insulin glargine adminis-
tered OD in 467 patients with type 2 diabetes   mellitus treated 
with metformin alone or in combination with a sulphonylu-
rea. Both treatment arms started with a baseline HbA1c level 
of 8.3%, and exenatide QW provided statistically significantly 
greater HbA1c reductions, weight loss versus weight gain, 
and fewer episodes of hypoglycemia compared with insulin 
glargine administered OD. Subjects in both treatment groups 
are continuing in an open-ended extension study. Results are 
expected in 2010.
In an ongoing randomized, double-blind trial, the   efficacy 
of 2 mg exenatide QW is being compared against that of 
metformin, sitagliptin, and pioglitazone as monotherapy 
in 822 drug-naive patients with type 2 diabetes mellitus 
(DURATION-4). The results are expected this year.
DURATION-5 study is a 26-week, 240-subject substudy 
designed to establish exenatide QW’s superiority over 
exenatide BID. The results are expected in 2010.
In summary, these efficacy data demonstrate that 
exenatide QW results in significantly improved glycemic con-
trol and targets multiple aspects of type 2 diabetes   mellitus. 
Exenatide QW has the additional therapeutic   advantages of 
greater fasting glucose and glucagon reductions and greater 
HbA1c level reductions by achieving constant and higher 
plasma drug concentrations.
Safety of exenatide QW
The most common side effects associated with exenatide 
BID include nausea, vomiting, and diarrhea, which are dose 
dependent and more common during drug initiation but 
subside over time.15
The risk of hypoglycemia is increased in patients on 
exenatide BID who also take a sulphonylurea,19 whereas 
it is not increased when exenatide BID is combined with 
metformin or a thiazolidiedione.25
Cases of acute pancreatitis have been reported with 
exenatide BID,26 but these are rare, and recent estimates 
indicate an incidence of 0.33–0.44 per 1,000 adults per 
year.27 Furthermore, the pancreatitis risk may be increased 
in patients with type 2 diabetes mellitus compared with 
nondiabetic patients, suggesting that the risk is related to 
the underlying disease state rather than being a complica-
tion of exenatide therapy.27 If pancreatitis is suspected, then 
exenatide treatment should be discontinued.26
Exenatide, being a synthetic version of a nonmamma-
lian hormone, has been associated with the development 
of antiexenatide antibodies when given as exenatide BID.20 
However, the presence of antiexenatide antibodies had no 
predictive effect on glycemic control or adverse events.20
Recently, the Food and Drug Administration (FDA) issued 
a safety warning on exenatide BID, associating it with the 
development of renal failure.28 This FDA warning was based 
on 78 postmarketing cases reported between April 2005 and 
October 2008. The average patient age in the case reports 
was 60 years. The FDA approved revisions to the drug label 
for exenatide because of the temporal – causal relationship 
that was observed with the initiation of exenatide and the 
occurrence of serious potential consequences of altered kidney 
function. Of the 78 cases reported, 62 cases were classified as 
acute renal failure and the remaining 16 cases were classified 
as renal insufficiency. The postmarketing surveillance data of 
these patients reported that after the initiation of exenatide, 
  hospitalization was required in 91% (71/78) of the patients. 
Kidney transplantation was required in 2 patients, and there 
were 4 fatalities. Dialysis had to be initiated in 18 patients, 
of which 2 patients had a known history of altered kidney 
  function. Upon discontinuation, 39 patients reported improved 
signs and symptoms, and recurrence of kidney dysfunction was 
reported in 1 patient who was reinitiated on exenatide BID.
In contrast to exenatide BID, exenatide QW appears to 
have a lower incidence of side effects. In DURATION-1 
study,23 exenatide QW was associated with a lower incidence 
of nausea compared with exenatide BID (26% vs 35%, 
respectively). Furthermore, patients on exenatide QW had a 
lower incidence of vomiting (11% vs 19%), and only 2 out 
of 148 patients on exenatide QW discontinued treatment 
because of these side effects.23
In DURATION-1 study,23 no patients on exenatide QW 
had a hypoglycemic episode if their background therapy did 
not include a sulphonylurea. With concurrent sulphonylurea 
use, 15% of patients reported a minor hypoglycemic event, 
similar to patients on exenatide BID. No major hypoglycemic 
episodes were reported.
There are currently no data on the incidence or risk 
of   pancreatitis associated with exenatide QW. However, 
concerns about pancreatitis only surfaced long after FDA Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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approval of exenatide BID. Of specific concern is the addi-
tional risk related to exenatide QW’s persistence after injec-
tion. For example, if pancreatitis occurs in an exenatide QW 
recipient, would it worsen over time because the drug takes 
3 weeks to wash out of the body, compared with 1 day for 
exenatide BID?
Injection site reactions have been associated with exenatide 
QW, consisting of small subcutaneous nodules, which may 
be accompanied by pain, induration, erythema, or bleeding.29 
Injection site pruritus is thought to be due to in vivo degradation 
of sustained-release delivery systems.30 This was observed in 
18% of patients on exenatide QW in DURATION-1 study23 
and was of mild intensity, which improved and then resolved 
with further exenatide treatment.23
Similar to patients on exenatide BID, antiexenatide 
antibodies have been observed in patients on exenatide QW, 
but antibodies were of low titers (,1/625).23 DURATION-1 
study found that antiexenatide antibody titers were higher 
with the once-weekly dosing rather than the twice-daily 
dosing (P = 0.0002). The significance of this finding is not 
clear. Antiexenatide antibodies have no predictive effect on 
glycemic control with exenatide BID, whereas there is no 
evidence to date as to how they may affect glycemic control 
with exenatide QW.23
The FDA has expressed specific concerns about 
  cardiovascular risk associated with new diabetes   medicines. 
In this regard, exenatide QW is relying heavily on a 
  meta-analysis of its parent compound, exenatide BID, that 
showed a reduced CVD risk of 0.70 compared with controls.31 
However, the main limitation of this study is the open-label, 
uncontrolled nature of the study design, which does not 
provide a placebo group for comparison.
Role of exenatide QW  
in clinical practice
There is emerging evidence that exenatide QW will have 
major effects on patient-focused perspectives such as 
quality of life, satisfaction, and compliance.32 In addition, 
  patient-reported measures can be used to examine whether 
drug differences other than clinical efficacy have an impact 
on outcomes that may be important to patients.
Exenatide QW may result in improved patient compliance 
compared with exenatide BID. Not surprisingly, patients 
seem to prefer taking a medication once a week rather than 
twice a day, suggesting exenatide QW would show improved 
compliance compared with exenatide BID. This simpler 
regimen could improve treatment adherence in real-world 
clinical settings.33
In a randomized, open-labeled, multicenter study,32 
  treatment satisfaction and weight-related quality of life 
in patients with type 2 diabetes mellitus treated with 
either exenatide BID or exenatide QW were assessed over 
1 year. Exenatide QW was shown to significantly reduce the 
  perceived frequency of hyperglycemia, ie, osmotic   symptoms, 
and improve overall patient satisfaction with   continued treat-
ment compared with exenatide BID. A quality-of-life analy-
sis revealed that patients reported higher overall treatment 
satisfaction with either exenatide BID (n = 147) or exenatide 
QW (n = 148) compared with their baseline therapy. Further-
more, in this study, treatment satisfaction and quality of life 
improved significantly for those switching from exenatide 
BID to exenatide QW. This study had the advantage of having 
a large sample size (n = 295) and a relatively long duration 
(52 weeks) to be able to detect clinically significant differ-
ences. In addition, the study outcomes, treatment satisfaction 
and quality of life, were assessed using validated question-
naires likely to be sensitive to the established clinical effects 
of the study medication. However, findings from this study 
were limited by the fact that there was no placebo group that 
continued with its prestudy medications to assess placebo 
effects and there was no crossover from exenatide QW to 
exenatide BID to assess order effects. Also, the participation 
of ethnic minorities was low, limiting the generalizability 
of the study findings to these groups, and the study did not 
examine outcomes for psychological well-being and diabetes 
distress for patients on exenatide QW.
Patient satisfaction for exenatide BID has been compared 
with that for insulin glargine in a randomized, 26-week 
  international trial that studied 549 patients with type 2 diabetes 
mellitus.34 This trial found that both exenatide and insulin 
glargine were associated with significant improvements in 
patient-reported outcomes when added to oral medications 
among patients with type 2 diabetes mellitus. Despite 
an additional daily injection and a higher rate of gastrointes-
tinal adverse events, treatment satisfaction of the exenatide 
group was comparable to that of the insulin glargine group, 
possibly because of weight loss observed in patients treated 
with exenatide. This trial34 had the advantage of using validated 
multiple scoring systems (the Vitality Scale of the SF-36, the 
Diabetes Symptom Checklist – Revised, the EuroQol EQ-5D, 
the Treatment Flexibility Scale, and the Diabetes Treatment 
Satisfaction Questionnaire) to accurately assess patient   outcome 
measures, which would increase the reliability of the findings. 
However, findings from the study were limited by a lack of 
generalizability as the study population was   predominantly 
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In a randomized, controlled trial,35 the long-term   clinical 
and economic outcomes associated with exenatide BID were 
compared with those associated with insulin glargine as 
“add-on” treatments to oral therapy in patients with type 2 
diabetes mellitus inadequately controlled with combination 
oral hypoglycemic agents in a computer simulation model 
of diabetes mellitus. This was used to project   complications, 
life expectancy, quality-adjusted life expectancy, and direct 
medical costs over a 35-year time horizon. Exenatide BID was 
associated with comparable life expectancy and an improve-
ment in quality-adjusted life expectancy versus insulin glargine 
over a 35-year time horizon. Based on   current standards, 
exenatide BID would be a cost-effective, alternative treatment 
to insulin glargine for patients with type 2 diabetes mellitus 
inadequately controlled with oral therapy. However, the find-
ings of this study are limited by a lack of both   reliability and 
validity to a real-world clinical environment.
Unlike exenatide BID, patient satisfaction with exenatide 
QW has not yet been compared with that with insulin glargine 
in a head-to-head study. However, as exenatide QW has a 
better gastrointestinal adverse effect profile than exenatide 
BID, one would expect improved patient satisfaction with 
exenatide QW compared with insulin glargine. Unlike 
exenatide BID, there are no economic or health outcome data 
comparing exenatide QW with insulin glargine.
There is some evidence from a murine model of 
  nonalcoholic steatohepatitis (NASH) that exenatide BID 
can reverse hepatic steatosis.36 In a preliminary study37 on 
31 patients for over 2 years, exenatide BID treatment led to 
a decrease in hepatic transaminase enzymes independent of 
weight loss. In a multicenter, double-blind,   placebo-controlled 
trial38 of 974 patients with type 2 diabetes mellitus, it was 
found that adjunctive exenatide treatment for 2 years resulted 
in a reduction in hepatic injury biomarkers, AST and ALT. 
Based on this observation, an as yet unpublished clinical trial 
sponsored by the National Institute of Diabetes and Diges-
tive and Kidney Diseases is under way, looking at whether 
exenatide BID administered subcutaneously for 24–28 weeks 
improves liver histology in diabetic patients with biopsy-
proven NASH. In contrast, there are no data on the potential 
disease-modifying role of exenatide QW in reversing NASH, 
and further research is needed in this area.
Other long-acting GLP-1 mimetics
Other GLP-1 mimetics that require less-frequent dosing than 
exenatide BID are currently available.
Liraglutide, a once-daily GLP-1 analog that has recently 
received FDA approval, was shown to enable many patients 
to achieve target HbA1c levels and to improve several 
  morbidities commonly associated with type 2 diabetes 
  mellitus. It induced weight loss, reduced systolic blood 
pressure, and improved β-cell function.39 It was well toler-
ated, although an increased incidence of mild nausea was 
observed.39 It has recently been licensed in the USA, Europe, 
and Japan.
However, recent concerns about C-cell medullary thy-
roid cancer associated with liraglutide, which has led to a 
“black-box” warning, may also need to be characterized 
for exenatide QW before it is approved by the FDA. Lira-
glutide has been associated with thyroid hyperplasia and 
medullary thyroid carcinoma. This occurs through GLP-1 
receptor stimulation of thyroid C-cells.39 As GLP-1 mimetics 
stimulate the same receptor in pancreatic β-cells that is also 
found in the C-cells of thyroid tissue, where the insidious 
medullary thyroid cancer forms, there is a theoretical risk 
that exenatide, being a related GLP-1 mimetic, may have a 
similar effect. However, rodent C-cell tumors induced by 
liraglutide are caused by a nongenotoxic, specific receptor-
mediated mechanism, to which rodents are particularly 
sensitive and humans are not.40 To date, there is no evidence 
of a causal relationship between exenatide and human C-cell 
medullary thyroid cancer.
Other GLP-1 mimetics include AVE0010,41 albiglutide,42 
and taspoglutide.43 All are currently not licensed.
In a Phase IIb trial41 of 542 patients, AVE0010 was found 
to be well tolerated and significantly improve glycemic con-
trol versus placebo in patients with type 2 diabetes mellitus 
inadequately controlled with metformin alone. The once-daily 
regimen demonstrated a clear dose response with a HbA1c level 
reduction similar to the reduction associated with the twice-
daily regimen. AVE0010 was also found to be associated with 
weight loss and postprandial glucose reductions.41
Albiglutide is a novel DPP-4-resistant GLP-1 dimer 
fused to human albumin.42 In clinical trials,42 albiglutide 
improved fasting plasma glucose and postprandial   glucose, 
with a favorable safety profile in subjects with type 2 
  diabetes   mellitus. Albiglutide’s long half-life may allow for 
  once-weekly or less-frequent dosing.
In a double-blind, placebo-controlled study,43   taspoglutide, 
a once-weekly human GLP-1 analog, when combined with 
metformin significantly improves fasting and postprandial 
glycemic control and induces weight loss, with a favorable 
tolerability profile.
However, unlike exenatide QW, none of these compounds 
have consistently demonstrated stable and sustained drug 
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Conclusion
All available treatments for type 2 diabetes mellitus have 
potential limitations such as daily administration and the need 
for dose titration. Adverse effects such as weight gain, fluid 
retention, gastrointestinal intolerability, and hypoglycemia have 
led to difficulty in achieving optimal control of type 2 diabetes 
mellitus. Given the rapidly increasing prevalence of diabetes 
mellitus and obesity worldwide, there is an urgent need for 
new, safe, and effective treatments, and incretin mimetics have 
emerged promising candidates that fulfil these criteria.
Exenatide BID is the first GLP-1 receptor agonist 
approved for the treatment of type 2 diabetes mellitus, and 
it lowers blood glucose by multiple mechanisms.
In clinical trials, exenatide QW has been shown to achieve 
better glycemic control compared with exenatide BID, with 
a lower incidence of adverse effects. Clinical trials have also 
demonstrated possible beneficial cardiovascular effects of 
exenatide QW. However, much remains to be discovered about 
this novel compound. Whether exenatide QW preserves β-cell 
mass and function and whether it has a disease-  modifying 
effect in NASH warrant further research. By slowing gastric 
emptying and reducing satiety, exenatide QW has been shown 
to facilitate weight loss. Whether exenatide QW could be 
investigated as an antiobesity treatment in patients with no 
type 2 diabetes mellitus warrants further research.
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